For the year ending 2025-12-31, KNSA has $763,633K in assets. $196,027K in debts. $165,596K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 165,596 | |||
| Short-term investments | 248,478 | |||
| Accounts receivable, net | 15,594 | |||
| Inventory | 54,895 | |||
| Prepaid expenses and other current assets | 42,614 | |||
| Total current assets | 527,177 | |||
| Property and equipment, net | 1,943 | |||
| Operating lease right-of-use assets | 9,807 | |||
| Other long-term assets | 11,307 | |||
| Intangible asset, net | 15,250 | |||
| Deferred tax assets | 198,149 | |||
| Total assets | 763,633 | |||
| Accounts payable | 2,028 | |||
| Accrued collaboration expenses | 70,015 | |||
| Accrued expenses | 42,020 | |||
| Operating lease liabilities | 2,987 | |||
| Other current liabilities | 22,134 | |||
| Total current liabilities | 139,184 | |||
| Non-current deferred revenue | 31,811 | |||
| Non-current operating lease liabilities | 6,510 | |||
| Other long-term liabilities | 18,522 | |||
| Total liabilities | 196,027 | |||
| Ordinary shares value-Common Class A | 12 | |||
| Ordinary shares value-Common Class B | 1 | |||
| Ordinary shares value-Common Class A1 | 4 | |||
| Ordinary shares value-Common Class B1 | 4 | |||
| Additional paid-in capital | 1,029,748 | |||
| Accumulated other comprehensive loss | -25 | |||
| Accumulated deficit | -462,138 | |||
| Total shareholders' equity | 567,606 | |||
| Total liabilities and shareholders' equity | 763,633 | |||
Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA)